Abstract:The beneficial and negative metabolites produced by gut microbiota. The gut microbiota produces all kinds of beneficial or negative metabolites and directly affects the intestinal barrier and gut hormone (GLP‐1 and PYY) release. After entering circulation, those metabolites regulate satiety, insulin release, adipose tissue function, and systemic immunity, thus influencing obesity and energy metabolism. Obesity is often associated with the risk of chronic inflammation and other metabolic diseases, such as diabetes, cardiovascular disease, and cancer. The composition and activity of the gut microbiota play an important role in this process, affecting a range of physiological processes, such as nutrient absorption and energy metabolism. The active gut microbiota can produce a large number of physiologically active substances during the process of intestinal metabolism and reproduction, including short‐chain/long‐chain fatty acids, secondary bile acids, and tryptophan metabolites with beneficial effects on metabolism, as well as negative metabolites, including trimethylamine N‐oxide, delta‐valerobetaine, and imidazole propionate. How gut microbiota specifically affect and participate in metabolic and immune activities, especially the metabolites directly produced by gut microbiota, has attracted extensive attention. So far, some animal and human studies have shown that gut microbiota metabolites are correlated with host obesity, energy metabolism, and inflammation. Some pathways and mechanisms are slowly being discovered. Here, we will focus on the important metabolites of gut microbiota (beneficial and negative), and review their roles and mechanisms in obesity and related metabolic diseases, hoping to provide a new perspective for the treatment and remission of obesity and other metabolic diseases from the perspective of metabolites.

Gut microbial metabolites in obesity, NAFLD and T2DM

Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity

Contribution of the gut microbiota to the regulation of host metabolism and energy balance: a focus on the gut–liver axis

Gut and obesity/metabolic disease: Focus on microbiota metabolites

The Role of the Gut Microbiota in Energy Metabolism and Metabolic Disease

The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus

Microbial Fermentation of Dietary Protein: An Important Factor in Diet–Microbe–Host Interaction

Gut microbial metabolite short-chain fatty acids and obesity

Microbial metabolites as modulators of host physiology

Gut microbiota and its metabolites: Bridge of dietary nutrients and obesity-related diseases

Butyrate to combat obesity and obesity‐associated metabolic disorders: Current status and future implications for therapeutic use

Gut microbiota and health: connecting actors across the metabolic system

Insights Into the Role of the Microbiome in Obesity and Type 2 Diabetes

The role of Gut Microbiota in the development of obesity and Diabetes

Intestinal microbiota and their metabolic contribution to type 2 diabetes and obesity

Importance of gut microbiota in obesity

Role of the intestinal microbiota in contributing to weight disorders and associated comorbidities

Nonalcoholic Fatty Liver Disease and the Intestinal Microbiome: An Inseparable Link

Gut Microbiota-Derived Metabolites in the Development of Diseases

Talking microbes: When gut bacteria interact with diet and host organs

Gut mycobiome and metabolic diseases: The known, the unknown, and the future